Oxford BioMedica PLC (LSE:OXB) used its capital markets day in London to set a long-term revenue target of £500 million by 2030, equivalent to a compound annual growth rate of 24% from its 2025 base, as the viral vector contract manufacturer seeks to rebuild momentum following the collapse of a takeover approach from private equity group EQT. The target extends the company's existing medium-term guidance, which points to revenues of between £344 million and £406 million by 2028, with growth of 25-30% in financial years 2027 and 2028 and an adjusted EBITDA margin above 20% by financial year 2027.